

# Recent trends in the number of patients with pathology samples indicating cancer in Northern Ireland

April 2021 Update

**NOTE: EXCLUDES ALTNAGELVIN HISTOLOGY DUE TO INCOMPLETE RECORDING OF PATHOLOGY RESULTS**

**Acknowledgements:** The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.



## Contents

	<u>Page</u>
Summary	3
Patients with pathology samples indicating cancer - All persons	7
Patients with pathology samples indicating cancer - Males	9
Patients with pathology samples indicating cancer - Females	11
Patients with pathology samples indicating cancer - Ages 0-69	13
Patients with pathology samples indicating cancer - Ages 70 and over	15
Patients with pathology samples indicating cancer - Belfast	17
Patients with pathology samples indicating cancer - Altnagelvin (Cytology only)	19
Patients with pathology samples indicating cancer - Antrim	21
Patients with pathology samples indicating cancer - Craigavon	23
Patients with pathology samples indicating bowel cancer - All persons	25
Patients with pathology samples indicating bowel cancer - All persons, screening age	27
Patients with pathology samples indicating lung cancer - All persons	29
Patients with pathology samples indicating breast cancer - Females	31
Patients with pathology samples indicating breast cancer - Females, screening age	33
Patients with pathology samples indicating prostate cancer - Males	35
Patients with pathology samples indicating gynaecological cancer - Females	37
Patients with pathology samples indicating upper gastrointestinal cancer - All persons	39
Patients with pathology samples indicating head & neck cancer - All persons	41
Patients with pathology samples indicating urinary cancer - All persons	43
Patients with pathology samples indicating haematological cancer - All persons	45
Patients with pathology samples indicating malignant melanoma - All persons	47
Patients with pathology samples indicating non-melanoma skin cancer - All persons	49
Patients with pathology samples indicating other cancer - All persons	51
Notes	53


## SUMMARY

### Recent trends in the number of patients with pathology samples indicating cancer: Apr-21

- 1) This summary provides an overview of recent trends in the number of patients with pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) whose first sample was taken from 01-Jan-20 to the week ending 17-Apr-21 in Northern Ireland.
- 2) These trends are contrasted with the annual average number of patients with pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.
- 3) Data are sourced from the four NHS pathology laboratories in Northern Ireland (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to the NI Cancer Registry on a monthly basis. Only cytology data from Altnagelvin is included due to incomplete recording of pathology results since the beginning of 2021.

#### Trends in patients with pathology samples indicating cancer by week first sample taken


- 4) From 01-Mar-20 to 17-Apr-21 the number of patients with a pathological sample indicating cancer was 10% lower than the average number for the same time period in 2017-2019.
- 5) Based upon the monthly trend in patients with pathology samples indicating cancer, there was an estimated shortfall of 1,040 patients during Mar-20 to Mar-21 compared to the expected number. Some of these "missing" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).



**Percentage change from 2017-2019 to 2021 in the number of patients with pathology samples indicating cancer, first taken in the weeks ending 20-Mar-21 to 17-Apr-21**

**6) Patient demographics**

There was a 1% increase in the number of patients with a pathology samples indicating cancer in the weeks ending 20-Mar-21 to 17-Apr-21 compared to the average value in the equivalent weeks in 2017-2019. There was a 4% decrease among males and a 5% increase among females. An increase of 4% was recorded in the number of patients aged 0-69 years, while a decrease of 4% occurred in the number aged 70 and older. Reductions were apparent in Belfast (8%), while increases were recorded in the other three laboratories (cytology only in Altnagelvin).



**7) Cancer type**

Compared to the annual average in 2017-2019, the number of patients with a pathology sample indicating lung cancer in the weeks ending 20-Mar-21 to 17-Apr-21 decreased by 18%, while those indicating gynaecological cancer decreased by 19% and those indicating urinary cancer decreased by 43%. Increases were recorded for bowel (16%), breast (12%) and prostate (23%) cancer. However, both types of skin cancer had decreases recorded.

**Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer, and estimates of the number of "missed" patients in 2020/2021: Patient demographics**

Patient demographics	Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer		Estimated number of "missed/additional" patients
	Weeks ending 20-Mar-21 to 17-Apr-21	Weeks ending 07-Mar-20 to 17-Apr-21	At the end of Mar-21
All persons	1%	-10%	1040 missed
<b><u>Gender</u></b>			
Males	-4%	-10%	430 missed
Females	5%	-11%	610 missed
<b><u>Age</u></b>			
Ages 0-69	4%	-11%	540 missed
Ages 70+	-4%	-10%	500 missed
<b><u>Pathology Lab</u></b>			
Belfast	-8%	-7%	410 missed
Altnagelvin**	12%	-3%	20 missed
Antrim	11%	-7%	90 missed
Craigavon	19%	-24%	520 missed

**\*\* (Cytology only)**

**Notes:**

"Missed" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).

"Missed/additional" patients were calculated based upon the difference between the actual and expected number of patients recorded. The latter is determined using the trend in patients diagnosed pathologically from Jan 2017 to Feb 2020, and thus includes any expected increases (or decreases) as a result in annual changes in the number of cases diagnosed (e.g. as a result of population growth and/or ageing).

**Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer, and estimates of the number of "missed" patients in 2020/2021: Cancer type**

Cancer type	Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer		Estimated number of "missed/additional" patients
	Weeks ending 20-Mar-21 to 17-Apr-21	Weeks ending 07-Mar-20 to 17-Apr-21	At the end of Mar-21
All cancers (ex NMSC)	1%	-10%	1040 missed
NMSC	-27%	-29%	1660 missed
Bowel	16%	-8%	150 missed
Lung	-18%	-22%	200 missed
Female breast	12%	-7%	30 missed
Prostate	23%	-9%	60 missed
Gynaecological	-19%	-20%	150 missed
Upper GI	4%	-15%	70 missed
Head & Neck	1%	-12%	70 missed
Urinary	-43%	-17%	30 missed
Haematological	-1%	1%	100 missed
Melanoma	-9%	-22%	160 missed
Other cancer	17%	2%	20 missed
<u>Screening age</u>			
Bowel cancer (Ages 60-74)	29%	-5%	90 missed
Breast cancer (Ages 50-70)	62%	2%	40 additional

**Notes:**

NMSC: Non-melanoma skin cancer; GI: Gastrointestinal


"Missed" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).

"Missed/additional" patients were calculated based upon the difference between the actual and expected number of patients recorded. The latter is determined using the trend in patients diagnosed pathologically from Jan 2017 to Feb 2020, and thus includes any expected increases (or decreases) as a result in annual changes in the number of cases diagnosed (e.g. as a result of population growth and/or ageing).


Other cancers excludes cancer of unknown primary.

## Patients with pathology samples indicating cancer (ex NMSC): All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	685	548	-20%
Feb-21	574	566	-1%
Mar-21	625	694	11%
Apr-21*	372	237	-36%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	159	139			
16-Jan-21	153	120			
23-Jan-21	156	136			
30-Jan-21	154	147			
06-Feb-21	154	152	776	694	-11%
13-Feb-21	123	169	740	724	-2%
20-Feb-21	151	106	738	710	-4%
27-Feb-21	145	140	727	714	-2%
06-Mar-21	149	148	722	715	-1%
13-Mar-21	147	132	715	695	-3%
20-Mar-21	129	147	722	673	-7%
27-Mar-21	150	179	721	746	4%
03-Apr-21	130	134	705	740	5%
10-Apr-21	146	70	702	662	-6%
17-Apr-21	97	125	652	655	1%


### By month and year first sample taken

Month/Year	Patients
Mar-19	589
Apr-19	611
May-19	738
Jun-19	603
Jul-19	673
Aug-19	618
Sep-19	675
Oct-19	778
Nov-19	670
Dec-19	579
Jan-20	697
Feb-20	631
Mar-20	587
Apr-20	352
May-20	468
Jun-20	609
Jul-20	564
Aug-20	558
Sep-20	655
Oct-20	605
Nov-20	699
Dec-20	633
Jan-21	548
Feb-21	566
Mar-21	694




## Patients with pathology samples indicating cancer (ex NMSC): Males


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**430**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	285
Apr-19	290
May-19	367
Jun-19	290
Jul-19	300
Aug-19	271
Sep-19	312
Oct-19	381
Nov-19	315
Dec-19	264
Jan-20	320
Feb-20	300
Mar-20	272
Apr-20	163
May-20	250
Jun-20	297
Jul-20	259
Aug-20	242
Sep-20	292
Oct-20	258
Nov-20	364
Dec-20	313
Jan-21	243
Feb-21	271
Mar-21	349

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	327	243	-26%
Feb-21	263	271	3%
Mar-21	302	349	15%
Apr-21*	175	90	-48%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	78	62			
16-Jan-21	71	57			
23-Jan-21	77	56			
30-Jan-21	72	66			
06-Feb-21	73	77	371	318	-14%
13-Feb-21	56	67	349	323	-7%
20-Feb-21	65	60	343	326	-5%
27-Feb-21	73	64	340	334	-2%
06-Mar-21	69	81	336	349	4%
13-Mar-21	68	61	331	333	1%
20-Mar-21	65	81	340	347	2%
27-Mar-21	74	86	349	373	7%
03-Apr-21	60	63	336	372	11%
10-Apr-21	75	31	342	322	-6%
17-Apr-21	39	40	313	301	-4%

## Patients with pathology samples indicating cancer (ex NMSC): Females


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**610**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	304
Apr-19	321
May-19	371
Jun-19	313
Jul-19	373
Aug-19	347
Sep-19	363
Oct-19	397
Nov-19	355
Dec-19	315
Jan-20	377
Feb-20	331
Mar-20	315
Apr-20	189
May-20	218
Jun-20	312
Jul-20	305
Aug-20	316
Sep-20	363
Oct-20	347
Nov-20	335
Dec-20	320
Jan-21	305
Feb-21	295
Mar-21	345

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	358	305	-15%
Feb-21	311	295	-5%
Mar-21	323	345	7%
Apr-21*	197	147	-26%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	82	77			
16-Jan-21	82	63			
23-Jan-21	79	80			
30-Jan-21	82	81			
06-Feb-21	80	75	405	376	-7%
13-Feb-21	67	102	391	401	3%
20-Feb-21	86	46	395	384	-3%
27-Feb-21	72	76	388	380	-2%
06-Mar-21	80	67	385	366	-5%
13-Mar-21	79	71	384	362	-6%
20-Mar-21	64	66	381	326	-15%
27-Mar-21	76	93	372	373	0%
03-Apr-21	70	71	369	368	0%
10-Apr-21	70	39	360	340	-6%
17-Apr-21	58	85	338	354	5%

## Patients with pathology samples indicating cancer (ex NMSC): Ages 0 to 69


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**540**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	328
Apr-19	344
May-19	422
Jun-19	339
Jul-19	380
Aug-19	344
Sep-19	399
Oct-19	438
Nov-19	373
Dec-19	336
Jan-20	380
Feb-20	361
Mar-20	339
Apr-20	216
May-20	276
Jun-20	333
Jul-20	298
Aug-20	315
Sep-20	351
Oct-20	349
Nov-20	399
Dec-20	360
Jan-21	322
Feb-21	325
Mar-21	400

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	404	322	-20%
Feb-21	340	325	-5%
Mar-21	367	400	9%
Apr-21*	212	151	-29%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	96	77			
16-Jan-21	89	77			
23-Jan-21	92	74			
30-Jan-21	95	90			
06-Feb-21	96	93	468	411	-12%
13-Feb-21	73	100	445	434	-2%
20-Feb-21	85	65	441	422	-4%
27-Feb-21	82	68	431	416	-3%
06-Mar-21	83	88	419	414	-1%
13-Mar-21	93	75	415	396	-5%
20-Mar-21	78	73	420	369	-12%
27-Mar-21	86	103	421	407	-3%
03-Apr-21	73	90	413	429	4%
10-Apr-21	80	46	409	387	-5%
17-Apr-21	59	78	376	390	4%

## Patients with pathology samples indicating cancer (ex NMSC): Ages 70 and over


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	281	226	-19%
Feb-21	234	241	3%
Mar-21	259	294	14%
Apr-21*	160	86	-46%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	63	62			
16-Jan-21	64	43			
23-Jan-21	64	62			
30-Jan-21	59	57			
06-Feb-21	57	59	308	283	-8%
13-Feb-21	50	69	295	290	-2%
20-Feb-21	66	41	297	288	-3%
27-Feb-21	64	72	296	298	1%
06-Mar-21	65	60	303	301	-1%
13-Mar-21	55	57	300	299	0%
20-Mar-21	52	74	302	304	1%
27-Mar-21	64	76	300	339	13%
03-Apr-21	56	44	292	311	6%
10-Apr-21	66	24	293	275	-6%
17-Apr-21	38	47	276	265	-4%


### By month and year first sample taken

Month/Year	Patients
Mar-19	261
Apr-19	267
May-19	316
Jun-19	264
Jul-19	293
Aug-19	274
Sep-19	276
Oct-19	340
Nov-19	297
Dec-19	243
Jan-20	317
Feb-20	270
Mar-20	248
Apr-20	136
May-20	192
Jun-20	276
Jul-20	266
Aug-20	243
Sep-20	304
Oct-20	256
Nov-20	300
Dec-20	273
Jan-21	226
Feb-21	241
Mar-21	294




## Patients with pathology samples indicating cancer (ex NMSC): Belfast laboratory


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**410**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	363
Apr-19	381
May-19	452
Jun-19	367
Jul-19	413
Aug-19	407
Sep-19	380
Oct-19	497
Nov-19	419
Dec-19	352
Jan-20	438
Feb-20	378
Mar-20	373
Apr-20	231
May-20	331
Jun-20	404
Jul-20	365
Aug-20	358
Sep-20	410
Oct-20	390
Nov-20	472
Dec-20	417
Jan-21	348
Feb-21	348
Mar-21	415

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	434	348	-20%
Feb-21	365	348	-5%
Mar-21	394	415	5%
Apr-21*	229	132	-42%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	100	91			
16-Jan-21	98	73			
23-Jan-21	96	83			
30-Jan-21	94	98			
06-Feb-21	99	93	488	438	-10%
13-Feb-21	79	102	466	449	-4%
20-Feb-21	95	69	464	445	-4%
27-Feb-21	95	82	462	444	-4%
06-Mar-21	95	92	463	438	-5%
13-Mar-21	89	82	453	427	-6%
20-Mar-21	85	103	459	428	-7%
27-Mar-21	96	91	459	450	-2%
03-Apr-21	82	75	446	443	-1%
10-Apr-21	92	43	443	394	-11%
17-Apr-21	56	65	410	377	-8%

## Patients with pathology samples indicating cancer (ex NMSC): Altnagelvin laboratory (Cytology only)


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**20**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	29
Apr-19	28
May-19	35
Jun-19	19
Jul-19	18
Aug-19	22
Sep-19	26
Oct-19	30
Nov-19	20
Dec-19	14
Jan-20	22
Feb-20	32
Mar-20	18
Apr-20	12
May-20	9
Jun-20	19
Jul-20	20
Aug-20	23
Sep-20	35
Oct-20	33
Nov-20	30
Dec-20	27
Jan-21	24
Feb-21	25
Mar-21	26

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	23	24	3%
Feb-21	19	25	29%
Mar-21	23	26	11%
Apr-21*	16	13	-17%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	3	6			
16-Jan-21	5	6			
23-Jan-21	5	5			
30-Jan-21	9	7			
06-Feb-21	3	6	25	30	20%
13-Feb-21	6	6	28	30	8%
20-Feb-21	5	2	27	26	-4%
27-Feb-21	5	11	27	32	19%
06-Mar-21	5	6	23	31	35%
13-Mar-21	6	3	26	28	8%
20-Mar-21	3	5	23	27	17%
27-Mar-21	8	8	26	33	25%
03-Apr-21	5	6	26	28	6%
10-Apr-21	5	5	27	27	1%
17-Apr-21	6	6	27	30	12%

## Patients with pathology samples indicating cancer (ex NMSC): Antrim laboratory


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**90**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	78
Apr-19	91
May-19	111
Jun-19	87
Jul-19	105
Aug-19	73
Sep-19	127
Oct-19	116
Nov-19	102
Dec-19	105
Jan-20	109
Feb-20	105
Mar-20	90
Apr-20	62
May-20	68
Jun-20	89
Jul-20	93
Aug-20	86
Sep-20	109
Oct-20	93
Nov-20	102
Dec-20	100
Jan-21	85
Feb-21	104
Mar-21	110

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	97	85	-12%
Feb-21	82	104	26%
Mar-21	88	110	25%
Apr-21*	57	44	-23%


\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	21	16			
16-Jan-21	20	20			
23-Jan-21	24	26			
30-Jan-21	22	22			
06-Feb-21	23	28	110	112	2%
13-Feb-21	18	30	107	126	18%
20-Feb-21	23	19	110	125	14%
27-Feb-21	18	28	103	127	23%
06-Mar-21	22	28	103	133	29%
13-Mar-21	20	20	101	125	24%
20-Mar-21	19	21	102	116	14%
27-Mar-21	19	32	98	129	32%
03-Apr-21	20	15	100	116	16%
10-Apr-21	21	16	100	104	4%
17-Apr-21	16	22	95	106	11%

## Patients with pathology samples indicating cancer (ex NMSC): Craigavon laboratory


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**520**

"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	119
Apr-19	111
May-19	140
Jun-19	130
Jul-19	137
Aug-19	116
Sep-19	142
Oct-19	135
Nov-19	129
Dec-19	108
Jan-20	128
Feb-20	116
Mar-20	106
Apr-20	47
May-20	60
Jun-20	97
Jul-20	86
Aug-20	91
Sep-20	101
Oct-20	89
Nov-20	95
Dec-20	89
Jan-21	91
Feb-21	89
Mar-21	143

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	131	91	-30%
Feb-21	107	89	-17%
Mar-21	120	143	19%
Apr-21*	70	48	-31%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	35	26			
16-Jan-21	30	21			
23-Jan-21	30	22			
30-Jan-21	30	20			
06-Feb-21	29	25	153	114	-25%
13-Feb-21	20	31	139	119	-14%
20-Feb-21	28	16	137	114	-17%
27-Feb-21	28	19	135	111	-18%
06-Mar-21	27	22	132	113	-15%
13-Mar-21	32	27	136	115	-15%
20-Mar-21	22	18	138	102	-26%
27-Mar-21	27	48	137	134	-2%
03-Apr-21	23	38	132	153	16%
10-Apr-21	27	6	132	137	4%
17-Apr-21	20	32	120	142	19%




## Patients with pathology samples indicating bowel cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**150**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	72
Apr-19	71
May-19	93
Jun-19	72
Jul-19	64
Aug-19	67
Sep-19	80
Oct-19	82
Nov-19	87
Dec-19	66
Jan-20	88
Feb-20	76
Mar-20	71
Apr-20	36
May-20	45
Jun-20	70
Jul-20	72
Aug-20	73
Sep-20	82
Oct-20	62
Nov-20	61
Dec-20	71
Jan-21	67
Feb-21	82
Mar-21	84

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	73	67	-8%
Feb-21	64	82	29%
Mar-21	72	84	16%
Apr-21*	48	39	-19%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	18	22			
16-Jan-21	18	14			
23-Jan-21	15	14			
30-Jan-21	13	13			
06-Feb-21	15	24	80	87	9%
13-Feb-21	16	29	77	94	22%
20-Feb-21	19	10	78	90	16%
27-Feb-21	18	21	81	97	20%
06-Mar-21	16	12	84	96	15%
13-Mar-21	16	19	85	91	7%
20-Mar-21	14	14	83	76	-9%
27-Mar-21	17	31	82	97	18%
03-Apr-21	20	17	84	93	11%
10-Apr-21	16	9	83	90	8%
17-Apr-21	13	22	80	93	16%


Note: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20).

## Patients with pathology samples indicating bowel cancer: All persons, screening age (60-74)


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**90**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	29
Apr-19	32
May-19	45
Jun-19	29
Jul-19	24
Aug-19	33
Sep-19	34
Oct-19	37
Nov-19	42
Dec-19	29
Jan-20	43
Feb-20	31
Mar-20	42
Apr-20	15
May-20	17
Jun-20	37
Jul-20	34
Aug-20	18
Sep-20	30
Oct-20	24
Nov-20	29
Dec-20	29
Jan-21	28
Feb-21	43
Mar-21	41

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	34	28	-17%
Feb-21	28	43	55%
Mar-21	32	41	28%
Apr-21*	21	19	-10%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	9	9			
16-Jan-21	10	6			
23-Jan-21	7	7			
30-Jan-21	5	4			
06-Feb-21	7	13	37	39	4%
13-Feb-21	7	17	36	47	31%
20-Feb-21	9	5	35	46	30%
27-Feb-21	6	10	34	49	43%
06-Mar-21	9	8	38	53	39%
13-Mar-21	8	9	39	49	25%
20-Mar-21	6	7	38	39	4%
27-Mar-21	7	11	35	45	27%
03-Apr-21	8	9	37	44	20%
10-Apr-21	7	6	35	42	19%
17-Apr-21	6	10	33	43	29%


Note: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20).

## Patients with pathology samples indicating lung cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**200**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	43
Apr-19	50
May-19	61
Jun-19	48
Jul-19	65
Aug-19	52
Sep-19	61
Oct-19	57
Nov-19	64
Dec-19	29
Jan-20	63
Feb-20	61
Mar-20	43
Apr-20	23
May-20	38
Jun-20	51
Jul-20	47
Aug-20	42
Sep-20	46
Oct-20	43
Nov-20	45
Dec-20	46
Jan-21	31
Feb-21	40
Mar-21	39

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	57	31	-45%
Feb-21	46	40	-13%
Mar-21	47	39	-18%
Apr-21*	30	21	-31%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	16	10			
16-Jan-21	11	3			
23-Jan-21	11	9			
30-Jan-21	15	9			
06-Feb-21	11	6	63	37	-42%
13-Feb-21	9	11	57	38	-33%
20-Feb-21	12	10	58	45	-23%
27-Feb-21	14	13	61	49	-20%
06-Mar-21	9	12	55	52	-5%
13-Mar-21	12	5	56	51	-9%
20-Mar-21	11	5	58	45	-22%
27-Mar-21	11	10	57	45	-21%
03-Apr-21	12	10	55	42	-24%
10-Apr-21	11	8	57	38	-34%
17-Apr-21	7	10	52	43	-18%


Note: Includes lung and trachea (ICD10 codes: C33-C34).

## Patients with pathology samples indicating breast cancer: Females


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**30**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	107
Apr-19	102
May-19	126
Jun-19	89
Jul-19	108
Aug-19	110
Sep-19	127
Oct-19	141
Nov-19	113
Dec-19	111
Jan-20	104
Feb-20	119
Mar-20	101
Apr-20	65
May-20	61
Jun-20	96
Jul-20	101
Aug-20	115
Sep-20	132
Oct-20	137
Nov-20	125
Dec-20	114
Jan-21	134
Feb-21	107
Mar-21	137

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	129	134	4%
Feb-21	101	107	6%
Mar-21	119	137	15%
Apr-21*	71	54	-24%

\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	25	31			
16-Jan-21	25	32			
23-Jan-21	30	37			
30-Jan-21	31	34			
06-Feb-21	27	26	137	160	17%
13-Feb-21	22	38	134	167	25%
20-Feb-21	28	18	137	153	12%
27-Feb-21	21	25	128	141	10%
06-Mar-21	29	30	126	137	8%
13-Mar-21	33	26	133	137	3%
20-Mar-21	24	25	135	124	-8%
27-Mar-21	26	30	133	136	3%
03-Apr-21	19	32	131	143	9%
10-Apr-21	29	18	131	131	0%
17-Apr-21	23	30	121	135	12%

Note: Includes female breast only (ICD10 codes: C50).




## Patients with pathology samples indicating breast cancer: Females, screening age (50-70)


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**40**  
"additional" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	48
Apr-19	40
May-19	66
Jun-19	39
Jul-19	57
Aug-19	55
Sep-19	75
Oct-19	76
Nov-19	61
Dec-19	60
Jan-20	52
Feb-20	56
Mar-20	56
Apr-20	35
May-20	25
Jun-20	38
Jul-20	43
Aug-20	68
Sep-20	75
Oct-20	76
Nov-20	77
Dec-20	60
Jan-21	74
Feb-21	68
Mar-21	91

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	68	74	8%
Feb-21	54	68	27%
Mar-21	59	91	54%
Apr-21*	32	32	1%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	14	17			
16-Jan-21	14	18			
23-Jan-21	15	16			
30-Jan-21	16	23			
06-Feb-21	13	18	72	92	27%
13-Feb-21	12	27	70	102	45%
20-Feb-21	17	11	73	95	30%
27-Feb-21	11	12	69	91	33%
06-Mar-21	15	21	68	89	32%
13-Mar-21	19	17	73	88	20%
20-Mar-21	10	16	72	77	7%
27-Mar-21	10	19	66	85	29%
03-Apr-21	8	21	63	94	50%
10-Apr-21	13	11	61	84	38%
17-Apr-21	11	18	52	85	62%


Note: Includes female breast only (ICD10 codes: C50).

## Patients with pathology samples indicating prostate cancer: Males


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**60**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	68
Apr-19	58
May-19	93
Jun-19	61
Jul-19	89
Aug-19	61
Sep-19	62
Oct-19	86
Nov-19	71
Dec-19	52
Jan-20	75
Feb-20	63
Mar-20	68
Apr-20	40
May-20	78
Jun-20	68
Jul-20	37
Aug-20	41
Sep-20	48
Oct-20	53
Nov-20	137
Dec-20	79
Jan-21	42
Feb-21	51
Mar-21	106

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	79	42	-47%
Feb-21	60	51	-15%
Mar-21	74	106	43%
Apr-21*	36	10	-72%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	20	12			
16-Jan-21	12	14			
23-Jan-21	19	0			
30-Jan-21	19	16			
06-Feb-21	17	20	87	62	-29%
13-Feb-21	13	7	80	57	-29%
20-Feb-21	16	12	84	55	-35%
27-Feb-21	11	11	77	66	-14%
06-Mar-21	17	20	75	70	-6%
13-Mar-21	20	9	77	59	-24%
20-Mar-21	17	43	81	95	17%
27-Mar-21	18	19	83	102	23%
03-Apr-21	10	19	82	110	35%
10-Apr-21	19	0	84	90	8%
17-Apr-21	8	7	72	88	23%


Note: (ICD10 codes: C61).

## Patients with pathology samples indicating gynaecological cancer: Females


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	60	31	-48%
Feb-21	51	43	-15%
Mar-21	57	48	-16%
Apr-21*	26	16	-39%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	12	5			
16-Jan-21	15	4			
23-Jan-21	12	7			
30-Jan-21	13	15			
06-Feb-21	15	12	67	43	-36%
13-Feb-21	9	18	64	56	-13%
20-Feb-21	12	7	61	59	-3%
27-Feb-21	15	6	65	58	-10%
06-Mar-21	15	11	66	54	-19%
13-Mar-21	14	13	65	55	-15%
20-Mar-21	10	4	66	41	-38%
27-Mar-21	13	17	67	51	-24%
03-Apr-21	11	8	63	53	-16%
10-Apr-21	7	7	56	49	-12%
17-Apr-21	8	4	50	40	-19%


Note: Includes uterus, ovary, cervix, vulva, vagina, placenta and other female genital (ICD10 codes: C51-C58).

### By month and year first sample taken


Month/Year	Patients
Mar-19	51
Apr-19	42
May-19	60
Jun-19	65
Jul-19	63
Aug-19	62
Sep-19	59
Oct-19	64
Nov-19	47
Dec-19	52
Jan-20	62
Feb-20	45
Mar-20	43
Apr-20	33
May-20	38
Jun-20	43
Jul-20	42
Aug-20	39
Sep-20	55
Oct-20	60
Nov-20	55
Dec-20	48
Jan-21	31
Feb-21	43
Mar-21	48

## Patients with pathology samples indicating upper gastrointestinal cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**70**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	29
Apr-19	27
May-19	32
Jun-19	25
Jul-19	30
Aug-19	35
Sep-19	31
Oct-19	32
Nov-19	25
Dec-19	28
Jan-20	43
Feb-20	29
Mar-20	23
Apr-20	14
May-20	18
Jun-20	28
Jul-20	22
Aug-20	19
Sep-20	30
Oct-20	32
Nov-20	28
Dec-20	29
Jan-21	18
Feb-21	24
Mar-21	36

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	31	18	-42%
Feb-21	26	24	-8%
Mar-21	30	36	20%
Apr-21*	17	13	-25%

\* Up to 17-Apr-21 only

### By week first sample taken


Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	7	2			
16-Jan-21	8	6			
23-Jan-21	7	5			
30-Jan-21	7	4			
06-Feb-21	8	14	37	31	-16%
13-Feb-21	7	3	37	32	-14%
20-Feb-21	4	3	33	29	-13%
27-Feb-21	9	5	35	29	-17%
06-Mar-21	7	11	34	36	5%
13-Mar-21	5	4	31	26	-17%
20-Mar-21	7	7	31	30	-4%
27-Mar-21	8	9	35	36	2%
03-Apr-21	7	9	33	40	20%
10-Apr-21	7	5	33	34	2%
17-Apr-21	4	4	33	34	4%

Note: Includes oesophagus and stomach (ICD10 codes: C15, C16).




## Patients with pathology samples indicating head & neck cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**70**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	16
Apr-19	30
May-19	32
Jun-19	38
Jul-19	24
Aug-19	30
Sep-19	26
Oct-19	36
Nov-19	30
Dec-19	28
Jan-20	31
Feb-20	20
Mar-20	20
Apr-20	12
May-20	15
Jun-20	21
Jul-20	31
Aug-20	27
Sep-20	24
Oct-20	26
Nov-20	30
Dec-20	30
Jan-21	22
Feb-21	41
Mar-21	27

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	31	22	-30%
Feb-21	22	41	84%
Mar-21	23	27	17%
Apr-21*	17	11	-34%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	7	6			
16-Jan-21	10	4			
23-Jan-21	7	2			
30-Jan-21	4	8			
06-Feb-21	6	18	34	38	12%
13-Feb-21	7	2	34	34	0%
20-Feb-21	4	8	29	38	33%
27-Feb-21	6	15	27	51	89%
06-Mar-21	5	6	28	49	73%
13-Mar-21	5	4	27	35	30%
20-Mar-21	5	7	25	40	58%
27-Mar-21	5	10	26	42	59%
03-Apr-21	8	3	28	30	6%
10-Apr-21	6	4	30	28	-6%
17-Apr-21	3	4	28	28	1%


Note: Includes lip, tongue, mouth, parotid & salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, nasal cavity, middle ear, sinuses and larynx (ICD10 codes: C00-C14, C30-C32).

## Patients with pathology samples indicating urinary cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**30**  
"missed" patients  
from start of Mar-20  
to the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	56
Apr-19	67
May-19	49
Jun-19	51
Jul-19	57
Aug-19	55
Sep-19	59
Oct-19	49
Nov-19	63
Dec-19	31
Jan-20	52
Feb-20	41
Mar-20	48
Apr-20	29
May-20	39
Jun-20	56
Jul-20	58
Aug-20	46
Sep-20	48
Oct-20	38
Nov-20	48
Dec-20	42
Jan-21	49
Feb-21	37
Mar-21	47

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	58	49	-15%
Feb-21	59	37	-37%
Mar-21	54	47	-13%
Apr-21*	39	10	-74%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	16	12			
16-Jan-21	14	6			
23-Jan-21	16	15			
30-Jan-21	10	16			
06-Feb-21	17	7	73	56	-23%
13-Feb-21	11	11	69	55	-20%
20-Feb-21	15	14	70	63	-10%
27-Feb-21	18	4	71	52	-27%
06-Mar-21	10	13	71	49	-31%
13-Mar-21	10	8	65	50	-23%
20-Mar-21	12	9	65	48	-26%
27-Mar-21	15	12	64	46	-28%
03-Apr-21	15	9	61	51	-17%
10-Apr-21	15	4	66	42	-36%
17-Apr-21	9	3	65	37	-43%


Note: Includes kidney, renal pelvis, ureter, bladder and other urinary (ICD10 codes: C64-C68).

## Patients with pathology samples indicating haematological cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**100**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	55
Apr-19	42
May-19	77
Jun-19	52
Jul-19	53
Aug-19	52
Sep-19	56
Oct-19	68
Nov-19	53
Dec-19	58
Jan-20	65
Feb-20	56
Mar-20	56
Apr-20	32
May-20	47
Jun-20	61
Jul-20	46
Aug-20	52
Sep-20	65
Oct-20	48
Nov-20	58
Dec-20	55
Jan-21	46
Feb-21	55
Mar-21	58

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	53	46	-13%
Feb-21	38	55	46%
Mar-21	44	58	31%
Apr-21*	23	18	-22%

\* Up to 17-Apr-21 only


### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	11	8			
16-Jan-21	12	14			
23-Jan-21	13	11			
30-Jan-21	10	13			
06-Feb-21	11	9	57	55	-4%
13-Feb-21	6	22	52	69	32%
20-Feb-21	10	6	50	61	22%
27-Feb-21	10	18	47	68	45%
06-Mar-21	12	18	49	73	49%
13-Mar-21	9	15	47	79	69%
20-Mar-21	8	7	48	64	33%
27-Mar-21	13	12	51	70	37%
03-Apr-21	9	6	50	58	15%
10-Apr-21	9	10	47	50	7%
17-Apr-21	5	8	43	43	-1%


Note: Includes lymphoma (all types), leukaemia (all types), myeloma, malignant immunoproliferative disease and other lymphoid and haematopoietic (ICD10 codes: C81-C96).

## Patients with pathology samples indicating malignant melanoma: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	24	24	0%
Feb-21	28	18	-35%
Mar-21	27	29	7%
Apr-21*	14	7	-51%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	3	5			
16-Jan-21	8	8			
23-Jan-21	5	4			
30-Jan-21	7	7			
06-Feb-21	8	4	31	28	-11%
13-Feb-21	7	4	35	27	-23%
20-Feb-21	7	6	34	25	-26%
27-Feb-21	7	4	36	25	-30%
06-Mar-21	5	6	34	24	-30%
13-Mar-21	7	6	33	26	-20%
20-Mar-21	6	8	32	30	-6%
27-Mar-21	6	6	31	30	-3%
03-Apr-21	4	3	28	29	2%
10-Apr-21	7	3	30	26	-12%
17-Apr-21	3	4	26	24	-9%

### By month and year first sample taken


Month/Year	Patients
Mar-19	28
Apr-19	38
May-19	32
Jun-19	20
Jul-19	29
Aug-19	21
Sep-19	31
Oct-19	51
Nov-19	42
Dec-19	28
Jan-20	40
Feb-20	30
Mar-20	37
Apr-20	18
May-20	14
Jun-20	19
Jul-20	19
Aug-20	28
Sep-20	27
Oct-20	15
Nov-20	34
Dec-20	22
Jan-21	24
Feb-21	18
Mar-21	29

Note: (ICD10 code: C43).




## Patients with pathology samples indicating non-melanoma skin cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	395	230	-42%
Feb-21	344	286	-17%
Mar-21	318	268	-16%
Apr-21*	162	88	-46%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	95	60			
16-Jan-21	88	62			
23-Jan-21	95	47			
30-Jan-21	96	60			
06-Feb-21	100	78	475	307	-35%
13-Feb-21	73	74	453	321	-29%
20-Feb-21	86	62	451	321	-29%
27-Feb-21	81	72	437	346	-21%
06-Mar-21	79	77	420	363	-14%
13-Mar-21	74	66	394	351	-11%
20-Mar-21	64	43	385	320	-17%
27-Mar-21	67	50	365	308	-16%
03-Apr-21	58	51	342	287	-16%
10-Apr-21	63	28	327	238	-27%
17-Apr-21	40	41	293	213	-27%


### By month and year first sample taken

Month/Year	Patients
Mar-19	316
Apr-19	342
May-19	341
Jun-19	349
Jul-19	356
Aug-19	345
Sep-19	378
Oct-19	428
Nov-19	431
Dec-19	299
Jan-20	438
Feb-20	359
Mar-20	297
Apr-20	61
May-20	140
Jun-20	244
Jul-20	236
Aug-20	239
Sep-20	314
Oct-20	306
Nov-20	387
Dec-20	270
Jan-21	230
Feb-21	286
Mar-21	268


Note: (ICD10 code: C44).

## Patients with pathology samples indicating other cancer: All persons


Patients with pathology samples indicating cancer, with first sample taken from 01-Mar-20 to 17-Apr-21




Patients with pathology samples indicating cancer by month first sample taken



Patients with pathology samples indicating cancer by week first sample taken




Percentage change between 2017-19 and 2021 in patients whose first pathology sample indicating cancer was taken in the previous five weeks



Note: Excludes histology from Altnagelvin laboratory due to incomplete recording of pathology results.

Note: Caution should be exercised in comparison of weekly April data as Easter week occurs at different times each year (Weeks ending: 10/4/21, 18/4/20, 27/4/19, 7/4/18, 22/3/17).

## Trend in patients with pathology samples indicating cancer by month and year first sample taken



**20**  
"missed" patients  
from start of Mar-20 to  
the end of Mar-21

### By month and year first sample taken

Month/Year	Patients
Mar-19	60
Apr-19	70
May-19	73
Jun-19	59
Jul-19	75
Aug-19	64
Sep-19	61
Oct-19	98
Nov-19	67
Dec-19	65
Jan-20	70
Feb-20	67
Mar-20	73
Apr-20	41
May-20	57
Jun-20	73
Jul-20	81
Aug-20	56
Sep-20	98
Oct-20	73
Nov-20	67
Dec-20	65
Jan-21	75
Feb-21	62
Mar-21	82

## DATA TABLES - Trend in patients with pathology samples indicating cancer

### By month first sample taken

Month	2017-2019 average	2021	Percentage change
Jan-21	76	75	-2%
Feb-21	61	62	2%
Mar-21	65	82	26%
Apr-21*	34	33	-4%

\* Up to 17-Apr-21 only

### By week first sample taken

Week ending	2017-2019 average	2021	Five-week rolling total		
			2017-2019 average	2021	Percentage change
09-Jan-21	16	21			
16-Jan-21	17	14			
23-Jan-21	21	22			
30-Jan-21	17	16			
06-Feb-21	16	14	87	87	0%
13-Feb-21	12	27	83	93	12%
20-Feb-21	16	8	82	87	6%
27-Feb-21	14	13	76	78	3%
06-Mar-21	19	18	78	80	3%
13-Mar-21	15	25	77	91	18%
20-Mar-21	13	18	77	82	6%
27-Mar-21	15	13	76	87	14%
03-Apr-21	12	16	74	90	21%
10-Apr-21	12	10	67	82	22%
17-Apr-21	10	16	62	73	17%

Note: Includes cancers of small intestine, anus, liver, gallbladder, thymus, bone, mesothelioma, soft tissue, penis, testis, eye, brain, endocrine system and thyroid (ICD10 codes: C16, C21-C26, C37-C41, C45-C49, C60, C62, C63, C69-C75).

Excludes cancer of unknown primary.

## Notes:

1. NMSC: Non-melanoma skin cancer
2. Data is sourced from the four NHS pathology laboratories in Northern Ireland (Altnagelvin, Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.
3. Figures represent the number of patients with pathology samples that indicated a malignant tumour and had this result coded and recorded by the end of Apr-21. Further samples taken up to Apr-21 may not yet have been recorded as a result was not available by the end of Apr-21. The presented figures may thus represent an undercount, particularly for later weeks. However, when comparisons are made with 2017-2019 the same limitation has been applied to all years in order to maintain comparability.
4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week (a Saturday) in 2020/2021. This is compared with the equivalent Sunday-Saturday week in 2017-2019, although the actual date ending this week in 2017-2019 will differ.
5. Individual patients with cancer may have more than one pathology sample. A diagnosis of cancer may be a result of more than one procedure indicating cancer, for example a breast cancer diagnosis may be based upon a positive biopsy of the breast and then a separate positive dissection of a lymph node. Patients are thus only included once per cancer type unless they have had pathology samples separated by more than two years, thus a patient with samples in March and April of 2019 will be counted once (in the March 2019 count), while a patient with samples in April 2017 and May 2020 will be counted in both the April 2017 and May 2020 counts.
6. "Missed" patients are calculated based upon the difference between the actual number of patients recorded compared to the number expected, which is based upon the trend in patients diagnosed pathologically from Jan 2017 to Feb 2020. It should be noted that these "missed" patients may be diagnosed clinically instead of pathologically (e.g. as a result of an emergency admission to hospital).

## Acknowledgements

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.

## Further Information

Further data is available at: [www.qub.ac.uk/nicr](http://www.qub.ac.uk/nicr)  
Phone: +44 (0)28 9097 6028  
e-mail: [nicr@qub.ac.uk](mailto:nicr@qub.ac.uk)

